http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2393157-C1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c90d4c9eb6f4837513dd1a4c6906f811 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_bc0a660b94e5a16da4df469e7951e6f8 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D487-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-519 |
| filingDate | 2008-10-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2010-06-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b6f8fe693a5ca0cd063a49b2d5201523 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0d091d90fa24958d7c920f69b17ad532 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a575e601380f594212e9e60d0992b6d2 |
| publicationDate | 2010-06-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2393157-C1 |
| titleOfInvention | 2-ALKYLAMINO-3-ARYLSULFONYL-PYRAZOLO[1,5-a]PYRIMIDINES, SEROTONIN 5-HT6 RECEPTOR ANTAGONISTS, METHODS OF PRODUCING AND USING SAID COMPOUNDS |
| abstract | FIELD: chemistry. n SUBSTANCE: present invention relates to novel 2-alkylamino-3-arylsulfonyl-pyrazolo[1,5-a]pyrimidines of general formula 1, their pharmaceutically acceptable salts and/or hydrates having serotonin 5-HT 6 receptor antagonist properties. The compounds can be used to treat and prevent development of various diseases of the central nervous system, pathogenesis of which is associated with 5-HT 6 receptors, particularly Alzheimer's disease, Parkinson's disease, Huntington disease, schizophrenia, other neurodegenerative diseases and cognitive disorders. In general formula 1 , R 1 is a hydrogen atom, C 1 -C 3 alkyl, C 1 -C 3 alkyloxyC 1 -C 3 alkyl, hydroxyC 1 -C 3 alkyl, adamantyl, optionally substituted phenyl, 5-6-member heterocyclyl containing a nitrogen or oxygen heteroatom, possibly condensed with a benzene ring; R 2 is a hydrogen atom, halogen atom, C 1 -C 3 alkyl, pyridyloxy; R 3 is a hydrogen atom; C 1 -C 3 alkyl; optionally substituted amino group selected from amino, mono- or di(C 1 -C 3 alkyl)amino, di(C 1 -C 3 alkyl)aminoC 2 -C 3 alkylamino, N-[di(C 1 -C 3 alkyl)aminoC 2 -C 3 alkyl]-N-(C 1 -C 3 alkyl)-amino; C 1 -C 3 alkyloxy, C 1 -C 3 alkyloxyC 1 -C 3 alkyl, hydroxyC 1 -C 3 alkyl; 6-member azaheterocyclyl, possibly containing an extra nitrogen or oxygen atom, a -N(C 1 -C 3 alkyl) group; R 4 is C 1 -C 3 alkyl; R 5 is a hydrogen atom, one or two halogen atoms or C 1 -C 3 alkyl. n EFFECT: design of a method of obtaining compounds, a pharmaceutical composition and a medicinal agent for treating and preventing various diseases of the central nervous system. n 25 cl, 12 dwg, 3 tbl, 20 ex |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2443697-C1 |
| priorityDate | 2008-10-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 197.